Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

Many lung cancers in nonsmokers have no known cause and are discovered only by chance.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Precancerous cells must adapt to and overcome cellular stress and inflammation in order to progress and form malignant tumors. Now, researchers at University of California San Diego School of Medicine ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

AI model calculates a protein-based stemness index to predict tumor aggressiveness and treatment resistance. Proteomic-based ...

Integrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of ...

Doctors may soon have a new tool in the fight against one of the most aggressive and lethal forms of cancer—in the form of an ...

Precancerous cells must adapt to and overcome cellular stress and inflammation in order to progress and form malignant tumors.

After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.